.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Value-Based Decision-Making in Metastatic Breast Cancer

Recommendations for treating HER2-positive metastatic breast cancer with newer HER2-targeted treatment approaches and considerations regarding their adoption into clinical practice.

EP. 1: Frontline Treatment Options for HER2+ Metastatic Breast Cancer

June 15th 2021

Frontline therapies available for newly diagnosed HER2-positive metastatic breast cancer and variables that impact treatment selection.

EP. 2: Newer Targeted Therapies for HER2+ Metastatic Breast Cancer

June 15th 2021

Ian E. Krop, MD, PhD, of Dana-Faber Cancer Institute, highlights more recent targeted therapy approvals for HER2-positive metastatic breast cancer and describes how each therapy is designed to work.

EP. 3: HER2+ MBC: Integrating Newer Targeted Therapies Into Practice

June 22nd 2021

Considerations regarding how to best integrate newer targeted therapies available for HER2-positive metastatic breast cancer [MBC] into clinical practice.

EP. 4: Sequencing HER2-Targeted Therapies in MBC

June 22nd 2021

Ian E Krop, MD, PhD, elaborates on which treatment settings are most appropriate to use HER2-targeted therapies in to manage metastatic breast cancer.

EP. 5: Dual HER2-Targeted Therapy for MBC

June 29th 2021

The rationale for treating metastatic breast cancer with a dual HER2-targeted therapy approach.

EP. 6: COVID-19 and the Use of HER2-Targeted Therapy for MBC

June 29th 2021

The impact of the COVID-19 pandemic on the utilization of newer targeted therapies for HER2-positive metastatic breast cancer and considerations regarding their adoption into clinical practice based on the availability of vaccines.

EP. 7: Frontline Treatment Standards for HER2+ mBC

July 21st 2021

Debra Patt, MD, PhD, MBA, describes the frontline standards of care and the factors involved in deciding on a treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer.

EP. 8: New Targeted Therapies for HER2+ mBC

July 21st 2021

An expert in HER2-positive metastatic breast cancer discusses the new targeted treatment regimens for patients.

EP. 9: Cost Considerations for HER2+ mBC Therapies

July 28th 2021

Debra Patt, MD, PhD, MBA, discusses the cost considerations of conventional and novel therapies for HER2-positive metastatic breast cancer.

EP. 10: How HER2+ mBC Targeted Therapies Impact Clinical Practice

July 28th 2021

Debra Patt, MD, PhD, MBA, explains how clinical practice has adapted to the use of targeted therapies to treat HER2-positive metastatic breast cancer.